Clinical Trials Logo

Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to Non-Hodgkin's Lymphoma.

Filter by:

NCT ID: NCT05370547 Recruiting - Clinical trials for Non Hodgkin's Lymphoma

Chidamide Bridging for CAR-T Therapy

Start date: May 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of CAR-T cells. This study will enroll approximately 120 subjects with recurrent or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Those with high expression of NOXA will receive conventional CAR-T treatment (without chidamide bridging), and those with low expression of NOXA will be randomly assigned 1:1 to those without or containing chidamide bridging. The purpose of this study was to evaluate the clinical response and safety of chidamide bridging.

NCT ID: NCT05349266 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Start date: March 18, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I, single center study to assess the efficacy and safety of ThisCART19A in adult with Non-Hodgkins Lymphoma in China.

NCT ID: NCT05206071 Recruiting - Clinical trials for Non-hodgkin's Lymphoma

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.

NCT ID: NCT05191225 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study

Start date: September 28, 2021
Phase: Phase 4
Study type: Interventional

The objective of this pilot study is therefore to assess the safety of Truxima ultrafast infusion within 30 minutes in patients with non-Hodgkin's lymphoma.

NCT ID: NCT05096234 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

Start date: September 28, 2021
Phase: Phase 2
Study type: Interventional

This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.

NCT ID: NCT04796675 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Start date: April 10, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD19 chimeric antigen receptor(CAR)-modified NK cells(CAR-NK-CD19) in patients with relapsed or refractory hematological malignancies.

NCT ID: NCT04666168 Recruiting - Clinical trials for Non-hodgkin's Lymphoma

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Start date: October 22, 2020
Phase: N/A
Study type: Interventional

This study is a multicenter, non randomized, single arm, open clinical trial. The selected disease was relapsed / refractory NHL, and the disease was classified into highly aggressive lymphoma, invasive lymphoma and inert lymphoma; Highly invasive NHL included Burkitt lymphoma (BL), lymphoblastic lymphoma (LBL), high-grade B-cell lymphoma, etc; Invasive NHL includes diffuse large B-cell lymphoma, mantle cell lymphoma and peripheral T-cell lymphoma; Inert NHL contains follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

NCT ID: NCT04662294 Recruiting - Multiple Myeloma Clinical Trials

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Start date: November 18, 2021
Phase: Early Phase 1
Study type: Interventional

A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases

NCT ID: NCT04586478 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: October 26, 2020
Phase: Phase 2
Study type: Interventional

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.

NCT ID: NCT04532203 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies